The improved BAM MSR (MultiScale Reference) method for estimation of copy number from NGS data in Nexus Copy Number 10.0 improves results for panel data where coverage across the genome is uneven allowing the software to perform well on a wide variety of NGS data.
EL SEGUNDO, Calif. (PRWEB) June 20, 2018
BioDiscovery’s Nexus Copy Number software is a leading solution for genomics researchers across the globe for integrated analysis of copy number, sequence variation, and LOH (loss of heterozygosity). The software is built on over two decades of research, design, and development in the genomics field and offers cutting-edge and user-friendly features to scientists worldwide.
Researchers around the world rely on Nexus Copy Number for accurate copy number calling. It is a highly robust, intuitive, and multi-platform software for both copy number calling and downstream statistical analyses. A key feature of Nexus Copy Number is its ability to derive high quality copy number calls from many flavors of NGS (whole exome, whole genome, shallow, targeted panel, and normal depth of coverage sequencing).
“Other methods that estimate copy number from NGS are typically created for a specific type of NGS data, manufacturer, and capture method and can’t be applied broadly,” said Dr. Soheil Shams, CEO, BioDiscovery, Inc. “Nexus Copy Number has built upon its 20 years of expertise in the field and its strength in copy number calling and technology agnostic features of its software to create a truly comprehensive solution for deriving copy number and allelic status from virtually any NGS technology. The improved BAM MSR (MultiScale Reference) method for estimation of copy number from NGS data in Nexus Copy Number 10.0 improves results for panel data where coverage across the genome is uneven allowing the software to perform well on a wide variety of NGS data. We’ve seen a huge interest from researchers using NGS data who now want to derive copy number from it and are pleased to be at the forefront of that movement.”
Nexus Copy Number 10.0 continues to provide an extensive list of statistical and visualization tools to perform large cohort studies: comparisons to identify statistically significant differences between subgroups, identification of cooperating events, clustering, gene enrichment, and more. With integration of sequence variant analysis along with copy number and AOH, Nexus Copy Number is a one-stop solution for data from a wide range of NGS and array technologies. Other features in version 10.0 include export of the distance matrix for clustering, user-specified event colors, and plotting of BAF (B-allele frequency) for the BAM ngCGH (matched) algorithm.
BioDiscovery’s platform-independent software packages provide a complete spectrum of data analysis solutions for gene expression (RNASeq, mRNA, miRNA) and copy number and sequence variation from microarray and NGS (WES, WGS, targeted panels) technologies. Nexus Copy Number is a user-friendly and robust software solution with specialized cancer specific tools and algorithms and the capability to handle large volumes of data. With its ability to handle virtually any genome and integrate data from different modalities (gene expression, copy number, sequence variation), it offers a more complete picture of the genomic landscape.
About BioDiscovery, Inc.
BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. The company’s mission is to enable scientists to eliminate disease and suffering through novel application of computational technologies and translating these findings directly and rapidly to clinical use.
From its inception in 1997, BioDiscovery has been an innovative leader in the genomics informatics field, having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. BioDiscovery’s passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system for clinical applications enabling research findings to make direct impact on patient care.
Contact BioDiscovery: 310-414-8100 or http://www.biodiscovery.com